CO7121320A2 - Anticuerpos anti-hla-b*27 y usos de estos - Google Patents

Anticuerpos anti-hla-b*27 y usos de estos

Info

Publication number
CO7121320A2
CO7121320A2 CO14241139A CO14241139A CO7121320A2 CO 7121320 A2 CO7121320 A2 CO 7121320A2 CO 14241139 A CO14241139 A CO 14241139A CO 14241139 A CO14241139 A CO 14241139A CO 7121320 A2 CO7121320 A2 CO 7121320A2
Authority
CO
Colombia
Prior art keywords
hla
antibodies
nexde
pesta
annexes
Prior art date
Application number
CO14241139A
Other languages
English (en)
Inventor
Andrew J Murphy
Ana Kostic
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CO7121320A2 publication Critical patent/CO7121320A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

VER PESTAÑA DE ANEXOS
CO14241139A 2012-04-02 2014-10-30 Anticuerpos anti-hla-b*27 y usos de estos CO7121320A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261618969P 2012-04-02 2012-04-02
US201361778703P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
CO7121320A2 true CO7121320A2 (es) 2014-11-20

Family

ID=48093122

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14241139A CO7121320A2 (es) 2012-04-02 2014-10-30 Anticuerpos anti-hla-b*27 y usos de estos

Country Status (22)

Country Link
US (1) US9790273B2 (es)
EP (1) EP2834272B1 (es)
JP (1) JP6320993B2 (es)
KR (1) KR20150003256A (es)
CN (1) CN104169302A (es)
AR (1) AR090585A1 (es)
AU (1) AU2013243644C1 (es)
BR (1) BR112014024622A2 (es)
CA (1) CA2868907C (es)
CL (1) CL2014002631A1 (es)
CO (1) CO7121320A2 (es)
EA (1) EA201491827A1 (es)
HK (1) HK1207092A1 (es)
IL (2) IL234707A0 (es)
MX (1) MX365690B (es)
MY (1) MY171180A (es)
NZ (1) NZ700650A (es)
PH (1) PH12014502184A1 (es)
SG (2) SG11201405759UA (es)
TW (1) TWI619729B (es)
UY (1) UY34721A (es)
WO (1) WO2013152001A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
SI2202245T1 (sl) 2007-09-26 2016-10-28 Chugai Seiyaku Kabushiki Kaisha Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
PL2275443T3 (pl) 2008-04-11 2016-05-31 Chugai Pharmaceutical Co Ltd Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny
MX365235B (es) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
EP2679681B2 (en) 2011-02-25 2023-11-15 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific FC antibody
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
CN104080909A (zh) 2011-11-30 2014-10-01 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
TWI619729B (zh) 2012-04-02 2018-04-01 再生元醫藥公司 抗－ｈｌａ－ｂ*２７抗體及其用途
ES2719720T3 (es) 2012-07-27 2019-07-12 Hope City Una vacuna de MVA para la administración de un complejo de UL128 y para prevenir la infección por CMV
US10919953B2 (en) 2012-08-24 2021-02-16 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific Fc region variant
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
EP2940135B9 (en) 2012-12-27 2021-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
CN113621057A (zh) 2013-04-02 2021-11-09 中外制药株式会社 Fc区变体
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
ES2807424T3 (es) * 2015-02-04 2021-02-23 Univ Zuerich Uso de homodímeros de hla-b27 para el tratamiento del cáncer
US9969800B2 (en) 2015-02-05 2018-05-15 Chugai Seiyaku Kabushiki Kaisha IL-8 antibodies
SG11201706774WA (en) * 2015-02-27 2017-09-28 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
TWI833684B (zh) 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體（ｃａｒ）、組合物及其使用方法
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
WO2017222593A1 (en) 2016-06-24 2017-12-28 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars), compositions and methods thereof
WO2017035185A1 (en) 2015-08-24 2017-03-02 University Of Cincinnati Methods and compositions for the detection of fc receptor binding activity of antibodies
WO2017044895A2 (en) 2015-09-10 2017-03-16 City Of Hope MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF
TW202231662A (zh) * 2015-12-18 2022-08-16 日商中外製藥股份有限公司 抗肌抑素抗體、含變異fc區之多肽及使用方法
PE20240365A1 (es) * 2015-12-18 2024-03-04 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y metodos de uso
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8
ES2949372T3 (es) 2016-08-10 2023-09-28 Univ Zuerich Confórmeros abiertos del CMH de clase Ia
US11608374B2 (en) 2017-01-30 2023-03-21 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
US20200114022A1 (en) 2017-03-31 2020-04-16 Alma Bio Therapeutics Methods of treatment of hla-b27 related inflammatory diseases and compositions related to same
JP2021502967A (ja) 2017-11-14 2021-02-04 中外製薬株式会社 抗Ｃ１ｓ抗体および使用方法
CN108486226B (zh) * 2018-04-01 2022-04-12 广东辉锦创兴生物医学科技有限公司 Hla-b27等位基因的检测试剂盒及其应用
IL286482B1 (en) * 2019-03-21 2024-09-01 Gamida Cell Ltd NK cell segments from culture for use in combination therapy
CN111175490A (zh) * 2020-01-19 2020-05-19 泛肽生物科技(浙江)有限公司 一种定性检测hla-b27的试剂盒及其检测方法
JP2024515240A (ja) * 2021-04-07 2024-04-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｍｈｃ－ｉ病の治療に使用するための組成物
EP4416286A1 (en) * 2021-10-14 2024-08-21 Regeneron Pharmaceuticals, Inc. Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (erap1) inhibitors
WO2023220263A1 (en) * 2022-05-13 2023-11-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for modulating tcr

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369010A (en) 1985-08-16 1994-11-29 Genetic Systems Corporation Monoclonal antibody to polymorphic HLA determinant -B27
EP0213824B1 (en) * 1985-08-16 1995-05-24 Genetic Systems Corporation Monoclonal antibody to polymorphic HLA determinant-B27
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US5734023A (en) * 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
US20130315933A1 (en) * 2010-10-06 2013-11-28 Christoph Renner Antibodies Directed Against HLA-B27 Homodimers and Methods and Uses Thereof in Diagnosis and Therapy
TWI619729B (zh) 2012-04-02 2018-04-01 再生元醫藥公司 抗－ｈｌａ－ｂ*２７抗體及其用途

Also Published As

Publication number Publication date
AU2013243644B2 (en) 2018-02-08
IL256716A (en) 2018-03-29
BR112014024622A2 (pt) 2017-08-08
MY171180A (en) 2019-09-30
AU2013243644A1 (en) 2014-10-23
CA2868907C (en) 2022-01-04
EP2834272B1 (en) 2020-06-24
KR20150003256A (ko) 2015-01-08
US9790273B2 (en) 2017-10-17
CA2868907A1 (en) 2013-10-10
TW201343675A (zh) 2013-11-01
PH12014502184A1 (en) 2014-12-10
IL234707A0 (en) 2014-11-30
AR090585A1 (es) 2014-11-26
EA201491827A1 (ru) 2015-03-31
UY34721A (es) 2013-10-31
TWI619729B (zh) 2018-04-01
MX365690B (es) 2019-06-11
SG11201405759UA (en) 2014-11-27
MX2014011898A (es) 2014-11-12
HK1207092A1 (en) 2016-01-22
US20130259876A1 (en) 2013-10-03
JP6320993B2 (ja) 2018-05-09
CN104169302A (zh) 2014-11-26
EP2834272A2 (en) 2015-02-11
SG10201608136SA (en) 2016-11-29
NZ700650A (en) 2017-02-24
WO2013152001A2 (en) 2013-10-10
CL2014002631A1 (es) 2015-01-16
AU2013243644C1 (en) 2018-05-10
JP2015514110A (ja) 2015-05-18
WO2013152001A3 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
CO7121320A2 (es) Anticuerpos anti-hla-b*27 y usos de estos
UY34876A (es) Anticuerpos anti-egfr y usos de los mismos
TWD180147S (zh) 淨水器
CL2015001321A1 (es) Anticuerpos anti-ceacam5 y usos de éstos
CO7151521A2 (es) Anticuerpos anti-fcrn
CL2016001212A1 (es) Moduladores de aplnr y usos de estos
MX2019006902A (es) Inmunoglobulinas heterodimericas.
PH12015502565B1 (en) Anti-transferrin receptor antibodies and methods of use
UY34680A (es) Anticuerpos humanos anti-cd27, métodos, y usos
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
CO7020877A2 (es) Anticuerpos anti-asic1 y usos de los mismos
BR112014026926A2 (pt) uso terapêutico de produtos de semente de chardonnay
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
DK2806892T3 (da) Kombineret terapeutisk anvendelse af antistoffer og endoglycosidaser
BR112015008272A2 (pt) cápsula para preparação de bebidas
BR112015012907A2 (pt) composição de cuidado pessoal
CO7151499A2 (es) Formulación inyectable
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
BR112015003032A2 (pt) anticorpos anti-jagged e métodos de utilização'.
CO7111295A2 (es) Anticuerpo anti-rob04
UY34702A (es) Composiciones y métodos agrícolas u hortícolas
GB2516581B (en) Culture of bacteriophage
CO7151533A2 (es) Promotores vegetales inducibles y su uso
UY34834A (es) Dispensación de artículos